Sarepta Names Former Abbvie President as CEO as Ingram Retires

Severino takes the helm at Sarepta after turbulent spell

Around five months after long-serving CEO Doug Ingram said he was stepping down, Sarepta has named industry veteran Michael Severino to replace him.

Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO

Most recently the leader of buzzy startup Tessera Therapeutics, Severino will look to improve the fortunes of a company facing emerging competition and declining sales for its prized gene therapy Elevidys.

Sarepta names Michael Severino, former Tessera CEO, as new chief executive

Severino is replacing Doug Ingram as the company tries to recover from a tumultuous year and a half and prepares for competition.

Sarepta names former Abbvie president as CEO as Ingram retires

Sarepta turns to Michael Severino as CEO, looking to move past recent turmoil

Sarepta Therapeutics has found its new CEO as it seeks to recover from a calamitous past year. Michael Severino will replace the company’s longtime leader Doug Ingram on Tuesday. Severino joins from Flagship’s gene editing ...